Abcam, ab305496, PE Anti-HOXB4 antibody [EP1919Y]

Size: 100µL
Rabbit Recombinant Monoclonal HOXB4 antibody - conjugated to PE. Suitable for Flow Cyt (Intra) and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EP1919Y,
Isotype:IgG,
Conjugation:PE,
Excitation/Emission:Ex: 480;565nm, Em: 578nm,
Carrier free:No,
Reacts with:Human,
Applications:Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
conjugated primary antibody
is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the
Lightning-Link® conjugation technology
, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Preservative: 0.02% Sodium azideConstituents: PBS, 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle, Store in the dark

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
HOXB4 is a homeobox protein that functions as a transcription factor and is alternatively known as Homeobox protein Hox-B4. It plays a role in the regulation of gene expression influencing cell differentiation and development. The molecular weight of HOXB4 is approximately 28 kDa. This protein is mostly expressed in embryonic tissues and certain adult tissues including the bone marrow where it plays a part in hematopoiesis.
Biological function summary
HOXB4 is essential in maintaining stem cell populations and directing hematopoietic stem cell differentiation. It does not form part of any large complex but it interacts with DNA to control the expression of specific genes critical for cellular development. By regulating these genes HOXB4 influences the proper formation of body structures during embryogenesis.
Pathways
HOXB4 is involved in the hematopoietic cell lineage and the anterior-posterior patterning pathway. It works alongside other Hox family proteins to establish the identity of cells and tissues along the body axis. A vital interaction exists with HOXA9 within these pathways which embodies collaborative control over blood cell formation and differentiation.
Abnormalities in HOXB4 expression link to certain types of leukemia and other blood-related disorders. Overexpression can lead to increased proliferation of hematopoietic stem cells causing a potential risk in developing acute myeloid leukemia. Interaction with proteins like HOXA9 has been observed in these contexts indicating a complex network of genetic regulation disruption associated with the onset of myeloproliferative diseases.